Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory tract congestion22.02.07.0030.006823%-
Lymphatic disorder01.09.01.003---
Cardiac flutter02.03.02.0120.000964%-
Epigastric discomfort07.01.02.0040.001640%-
Musculoskeletal discomfort15.03.04.0010.002942%-
Organ failure08.01.03.0410.000723%-
Skin swelling23.03.03.0390.001640%-
Dental discomfort07.09.06.0020.000820%-
Cerebral disorder17.02.10.0170.002363%-
Dysphemia17.02.08.010; 19.19.03.0050.001471%-
Urine odour abnormal20.02.01.0200.002122%-
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.010802%-
Chronic inflammatory demyelinating polyradiculoneuropathy10.04.10.004; 17.09.04.0040.000241%-
Anxiety disorder19.06.01.0020.001230%-
Cancer pain16.32.03.0040.000772%-
Angiopathy24.03.02.0070.001013%-
Hepatic enzyme increased13.03.04.028---
Ischaemic cerebral infarction17.08.01.022; 24.04.06.0130.000241%-
Adverse event08.06.01.0100.041568%-
Appetite disorder14.03.01.004; 19.09.01.0020.003110%-
Bladder disorder20.03.01.0020.003834%-
Breast disorder21.05.04.0040.001181%-
Cardiac disorder02.11.01.0030.035661%-
Connective tissue disorder10.04.04.026; 15.06.01.006---
Diabetic complication05.07.03.002; 14.07.03.0020.000241%-
Eyelid disorder06.08.03.010; 23.03.03.0280.000820%-
Feeding disorder14.03.02.003; 19.09.01.0030.004485%-
Foetal disorder18.03.02.001---
Embolism24.01.01.009--
Gastrointestinal motility disorder07.02.03.0010.001640%-
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 16 Pages